Verbatim response from Claude
This is a rapidly changing situation, so I want to be straightforward with you:
What Happened
The FDA declared the semaglutide shortage over (early 2025), which banned most compounding pharmacies from making compounded semaglutide (Ozempic/Wegovy). Tirzepatide (Mounjaro/Zepbound) followed shortly after.
Current Landscape (as of mid-2025)
Some telehealth services are still navigating this legally:
- Hims & Hers - shifted away from compounded semaglutide but explore alternatives
- BodyLogicMD - works with 503B compounders which have different rules
- Calibrate - focuses on branded medications
- Henry - pivoted toward branded options
Important Caveats I Should Be Honest About
- This changes week to week due to ongoing legal challenges
- Some providers claiming to still offer compounded GLP-1s may be operating in legal gray areas
- 503A vs 503B pharmacy rules differ significantly
- Some services offer "salts" versions (semaglutide sodium) - legality is disputed
My Honest Recommendation
Consult directly with services like Ro, Noom Med, or Found and ask specifically about their current formulary. Also check GoodRx for manufacturer savings programs on branded versions.
Would you like help finding affordable branded alternatives instead?